Eli Lilly and Company (NYSE:LLY) Trading Down 3.9% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) fell 3.9% during mid-day trading on Tuesday . The stock traded as low as $993.58 and last traded at $1,003.2090. 5,412,469 shares changed hands during mid-day trading, an increase of 77% from the average session volume of 3,050,505 shares. The stock had previously closed at $1,044.13.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large manufacturing build-out signals capacity to meet demand for GLP‑1 drugs and other injectables — expands production footprint with a new $3.5B Pennsylvania site and broader U.S. capacity additions. Eli Lilly plans $3.5B injectable manufacturing site in Pennsylvania
• Positive Sentiment: Analysts expect a revenue beat for Q4 driven by strong GLP‑1 (Mounjaro, Zepbound) sales, supporting higher top-line guidance into the quarter. Eli Lilly Expected to Report Higher 4Q Profit, Revenue — Earnings Preview
• Positive Sentiment: Pipeline and R&D partnerships broaden future growth prospects — new collaborations with Zonsen PepLib and Repertoire Immune Medicines add discovery assets and modality diversity. Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with Lilly Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines
• Positive Sentiment: Targeted investments and M&A moves: Lilly to buy 5% of Veradermics in its IPO (hair‑loss focus) and is pursuing a cash deal for Ventyx — these extend non‑GLP‑1 franchise opportunities. Eli Lilly (LLY) to Buy 5% of Veradermics Stock in IPO Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
• Positive Sentiment: High‑profile commentary (Jim Cramer) notes potential upcoming data releases that could re‑ignite momentum if positive. Jim Cramer says Eli Lilly could announce some new data, and that could get the stock rolling
• Neutral Sentiment: Mixed Wall Street outlook pieces summarize bullish revenue drivers but show varied analyst ratings and price targets — sentiment is not unanimous. Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: Earnings season previews and buy/hold analyses highlight sector context; these are informational ahead of the official Q4 release. What’s in Store for These 5 Pharma Bigwigs This Earnings Season?
• Negative Sentiment: Competitive pressure and falling U.S. prices for GLP‑1 drugs are tightening the long‑term obesity market opportunity, which could cap future revenue growth. Obesity market sales potential tightens as Novo and Lilly enter new era
• Negative Sentiment: Analysts warn rising R&D and expansion costs may pressure near‑term profits despite revenue strength — a key risk for upcoming EPS figures. Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&D Costs Could Drag Profits

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Rothschild & Co Redburn lifted their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,162.75.

Eli Lilly and Company Stock Performance

The stock has a market cap of $948.41 billion, a PE ratio of 49.08, a P/E/G ratio of 0.78 and a beta of 0.39. The stock has a 50-day moving average of $1,056.39 and a 200 day moving average of $892.18. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently made changes to their positions in LLY. Lazard Freres Gestion S.A.S. increased its stake in Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after buying an additional 41,222 shares during the period. Exencial Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after buying an additional 11,396 shares during the period. Rede Wealth LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at approximately $487,000. Central Pacific Bank Trust Division increased its position in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares during the last quarter. Finally, Capital Advisors Inc. OK lifted its position in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after purchasing an additional 429 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.